The University of Puerto Rico Clinical Trials Unit (UPR-CTU) is a coalition/merge of the three previous independent Clinical Trials Sites associated to the AACTG, HVTN and PACTG Networks. The newly formed UPR-CTU will continue to have 3 Clinical Research Sites which will work with the Leadership Networks established to further advance the high priority areas related to: Vaccine Research and Development, Translational Research/Drug Development, Optimization of Clinical management, including Co-Morbidities and Prevention of Mother to Child Transmission of HIV. Letters confirming our affiliation to the following Networks are included in section h. (Consortium and Contractual Agreements): AIDS Clinical trials Group (ACTG), International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) and the HIV Vaccine Trials Network (HVTN). The Goals of the UPR-CTU are to integrate three previously independent clinical research units into a single complex but operationally efficient Clinical Trials Unit. Improved efficiency and expansion of services will be the result of the integration/merge of specific units or functions within units. For example: a centralized pharmacy with better infrastructure will be able to provide quality services and expanded functions. Cost containment is expected since mayor infrastructure investments will be localized to a central site. Community interaction including community education and recruitment will also be integrated or merged in order to maximize resources and outcomes. The UPR-CTU already has a centralized laboratory which has provided services and support to the three previously independent units. The scientific input and expertise of the Laboratory Director will be incorporated into the Executive Committee composed of the co-investigators. The UPR-CTU has the access and capacity to recruit the following populations: men and women living with HIV (mostly Hispanic minorities) either treatment naive or experienced, pregnant women living with HIV, infants born to women living with HIV, infants, children and adolescents exposed to HIV or infected with HIV, Low (behavioral) risk HIV negative volunteers (men and women), High risk heterosexual women (commercial sex workers, crack/drug users, sex partners of IDUs) and High risk MSM. Not only operational efficiency is expected but also, future research collaborations within networks will be simplified at the units. The expertise for vaccine trials, adolescent medicine, special populations, women (pregnant and non-pregnant) and minority issues just to mention a few, can be shared between the clinical research sites.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-AR-A (M1))
Program Officer
Welsch, Sue A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Puerto Rico Med Sciences
Obstetrics & Gynecology
Schools of Medicine
San Juan
United States
Zip Code
Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305). J Infect Dis 215:238-246
Verma, Anurag; Bradford, Yuki; Verma, Shefali S et al. (2017) Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202. Pharmacogenet Genomics 27:101-111
Riddler, Sharon A; Aga, Evgenia; Bosch, Ronald J et al. (2016) Continued Slow Decay of the Residual Plasma Viremia Level in HIV-1-Infected Adults Receiving Long-term Antiretroviral Therapy. J Infect Dis 213:556-60
Landovitz, Raphael J; Tran, Thuy Tien T; Cohn, Susan E et al. (2016) HIV Transmission Risk Behavior in a Cohort of HIV-Infected Treatment-Naïve Men and Women in the United States. AIDS Behav 20:2983-2995
Chan, Ellen S; Landay, Alan L; Brown, Todd T et al. (2016) Differential CD4+ cell count increase and CD4+?: ?CD8+ ratio normalization with maraviroc compared with tenofovir. AIDS 30:2091-7
Verma, Shefali S; Frase, Alex T; Verma, Anurag et al. (2016) PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG). Pac Symp Biocomput 21:57-68
Tashima, Karen T; Smeaton, Laura M; Fichtenbaum, Carl J et al. (2015) HIV Salvage Therapy Does Not Require Nucleoside Reverse Transcriptase Inhibitors: A Randomized, Controlled Trial. Ann Intern Med 163:908-17
Tenorio, Allan R; Chan, Ellen S; Bosch, Ronald J et al. (2015) Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. J Infect Dis 211:780-90

Showing the most recent 10 out of 52 publications